{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:56Z","timestamp":1793134136821,"version":"4.5.0"},"reference-count":59,"publisher":"Informa UK Limited","issue":"13","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.2217\/fon-2019-0013","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T16:34:19Z","timestamp":1551371659000},"page":"1411-1428","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":32,"title":["INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma"],"prefix":"10.1080","volume":"15","author":[{"given":"Caitlin","family":"Costello","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Blood and Marrow Transplantation,\u00a0Moores Cancer Center, University of California San Diego, La Jolla, CA92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E","family":"Davies","sequence":"additional","affiliation":[{"name":"Myeloma Institute, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leeds Cancer Centre, St James's University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Vela-Ojeda","sequence":"additional","affiliation":[{"name":"Hematology Department, La Raza Medical Center, IMSS, M\u00e9xico City, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Omel","sequence":"additional","affiliation":[{"name":"The Central Nebraska Myeloma Support Group, Grand Island, NE68801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Department of Hematology Research, US Oncology Research\/Rocky Mountain Cancer Centers, Denver, CO80218, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sarah Cannon Research Institute, Nashville, TN37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z","family":"Usmani","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Tuebingen, Tuebingen, Germany"},{"name":"Department of Oncology, Hematology & Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Zonder","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute\/Wayne State University School of Medicine, Detroit, MI48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National & Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Alfred Health-Monash University,\u00a0Melbourne\rAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"P\u00f4le R\u00e9gional de Canc\u00e9rologie and CIC1402 INSERM, CHU de Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Thompson","sequence":"additional","affiliation":[{"name":"Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI53215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Romanus","sequence":"additional","affiliation":[{"name":"\u00a0Global Outcomes Research, Millennium Pharmaceuticals, Inc., Cambridge, MA02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M","family":"Stull","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Millenium Pharmaceuticals, Inc., Cambridge, MA02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinica S\u00e3o Germano and Santa Casa Medical School, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.005"},{"key":"e_1_3_6_5_1","unstructured":"National Cancer Institute SEER Cancer Statistics Review 1975\u20132015 (2018). https:\/\/seer.cancer.gov\/csr\/1975_2015\/results_merged\/sect_18_myeloma.pdf."},{"key":"e_1_3_6_6_1","unstructured":"Cancer Research UK . Myeloma survival statistics (2014). www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/survival#heading-Two."},{"key":"e_1_3_6_7_1","unstructured":"Office for National Statistics . Cancer survival in England: adult stage at diagnosis and childhood \u2013 patients followed up to 2016 (2015). www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/cancersurvivalinengland\/adultstageatdiagnosisandchildhoodpatientsfollowedupto2016#cancer-survival-in-england-patients-diagnosed-between-2011-and-2015-and-followed-up-to-2016-national-statistics."},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183475"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0132-1"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9707-8"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19269"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.174573"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0002"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1418856"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.11.016"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_3_6_19_1","volume-title":"American Society of Hematology 59th Annual Meeting & Exposition","author":"Chari A","year":"2017","unstructured":"Chari A , RomanusD, LuptakovaKet al. Duration of therapy (DOT) and time to next therapy (TTNT) of bortezomib, carfilzomib and ixazomib combinations with lenalidomide\/dexamethasone (VRd, KRd, IRd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): clinical practice in the United States vs clinical trial experience. Presented at: American Society of Hematology 59th Annual Meeting & Exposition. Atlanta, GA, USA, 9\u201312 December 2017."},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7916"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.101"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.148"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1170828"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010512"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2644-6"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1195254"},{"key":"e_1_3_6_28_1","volume-title":"16th International Myeloma Workshop","author":"Romanus D","year":"2017","unstructured":"Romanus D , RajuA, SealBet al. Treatment (tx) patterns & outcomes by line of therapy (LOT) in a large United States (US) cohort of transplant-ineligible patients (pts) with multiple myeloma in the era of novel agents. Presented at: 16th International Myeloma Workshop. New Delhi, India, 1\u20134 March 2017."},{"key":"e_1_3_6_29_1","volume-title":"American Society of Hematology 59th Annual Meeting & Exposition","author":"Terpos E","year":"2017","unstructured":"Terpos E , MaoucheN, MinarikJ, KatodritouE, JennerM, PlonkovaH. \u201cReal world\u201d data on the efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a combined study from the Greek, Czech and UK databases. American Society of Hematology 59th Annual Meeting & Exposition. Atlanta, GA, USA, 9\u201312 December 2017."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e19522"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4516.4516"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1437345"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.185"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"e_1_3_6_36_1","volume-title":"23rd Congress of the European Hematology Association","author":"Boccadoro M","year":"2018","unstructured":"Boccadoro M , UsmaniSZ, ChariAet al. A global treatment standard in multiple myeloma (MM) remains elusive despite advances in care over 15 years: first results from INSIGHT MM, the largest global prospective, observational MM study. 23rd Congress of the European Hematology Association. Stockholm, Sweden, 14\u201317 June 2018."},{"key":"e_1_3_6_37_1","volume-title":"American Society of Hematology 60th Annual Meeting & Exposition","author":"Usmani SZ","year":"2018","unstructured":"Usmani SZ , HungriaVTM, Xavier LeleuXet al. Transplant status does not impact the selection of induction regimens for newly diagnosed multiple myeloma (NDMM) patients (pts) in the INSIGHT MM prospective, observational study. American Society of Hematology 60th Annual Meeting & Exposition. San Diego, CA, USA, 1\u20134 December 2018."},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.14735\/amko20172S43"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0250-z"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120121"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.05.007"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.346"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.10.008"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0397-7"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"issue":"1","key":"e_1_3_6_46_1","first-page":"5419","article-title":"Uncovering the blind spot of clinical trials: first report of baseline characteristics of newly diagnosed (ND) and relapsed\/refractory (RR) multiple myeloma (MM) patients (pts) in INSIGHT-MM, a global, prospective, observational study","volume":"130","author":"Terpos E","year":"2017","unstructured":"Terpos E , ChariA, RifkinRMet al. Uncovering the blind spot of clinical trials: first report of baseline characteristics of newly diagnosed (ND) and relapsed\/refractory (RR) multiple myeloma (MM) patients (pts) in INSIGHT-MM, a global, prospective, observational study. Blood130(Suppl. 1), 5419 (2017).","journal-title":"Blood"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2350.2350"},{"key":"e_1_3_6_48_1","unstructured":"Multiple Myeloma Research Foundation . MMRF CoMMpass Study (2018). https:\/\/themmrf.org\/we-are-curing-multiple-myeloma\/mmrf-commpass-study\/."},{"issue":"1","key":"e_1_3_6_49_1","first-page":"3156","article-title":"Baseline disease characteristics and diagnostic patterns for NDMM of the Connect\u00ae MM registry: observations over time in cohort 1 (2009\u20132011) and cohort 2 (2012\u20132016)","volume":"130","author":"Narang M","year":"2017","unstructured":"Narang M , AbonourR, DurieBGMet al. Baseline disease characteristics and diagnostic patterns for NDMM of the Connect\u00ae MM registry: observations over time in cohort 1 (2009\u20132011) and cohort 2 (2012\u20132016). Blood130(Suppl. 1), 3156 (2017).","journal-title":"Blood"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4489.4489"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.018"},{"issue":"1","key":"e_1_3_6_52_1","first-page":"3123","article-title":"Treatment patterns and associated outcomes in patients with relapsed or refractory multiple myeloma in the US and non-US countries: Findings from PREAMBLE","volume":"130","author":"Vij R","year":"2017","unstructured":"Vij R , ChenC, PopovSet al. Treatment patterns and associated outcomes in patients with relapsed or refractory multiple myeloma in the US and non-US countries: Findings from PREAMBLE. Blood130(Suppl. 1), 3123 (2017).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_6_53_1","first-page":"3157","article-title":"Healthcare resource utilization and costs associated with different treatment modalities of relapsed\/refractory multiple myeloma patients in the US: findings from PREAMBLE","volume":"130","author":"Kuter DJ","year":"2017","unstructured":"Kuter DJ , ChenC, PopovS, DavisC, Ravi VijR. Healthcare resource utilization and costs associated with different treatment modalities of relapsed\/refractory multiple myeloma patients in the US: findings from PREAMBLE. Blood130(Suppl. 1), 3157 (2017).","journal-title":"Blood"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.229"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-0953-4"},{"key":"e_1_3_6_56_1","unstructured":"Ba\u0159inov\u00e1 M . Registry of monoclonal gammopathies (RMG) (2019)."},{"key":"e_1_3_6_57_1","unstructured":"Spencer A . Australian and New Zealand myeloma and related diseases registry (MRDR) (2019)."},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0785-z"},{"key":"e_1_3_6_59_1","volume-title":"21st Congress of the European Hematology Association","author":"Verelst S","year":"2016","unstructured":"Verelst S , BlommesteinH, Gonzalez-McQuireSet al. Overall survival in patients with symptomatic multiple myeloma in the real-world setting: a retrospective analysis of the PHAROS registry in The Netherlands. 21st Congress of the European Hematology Association. Copenhagen, Denmark, 9\u201312 June 2016."},{"key":"e_1_3_6_60_1","volume-title":"22nd Congress of the European Hematology Association","author":"Wester R","year":"2017","unstructured":"Wester R , DinmohamedA, SonneveldP, BroijlA, BlijlevensN. Pomalidomide with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a prospective analysis in a population-based registry. 22nd Congress of the European Hematology Association. Madrid, Spain, 22\u201325 June 2017."},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-018-0383-3"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:22Z","timestamp":1719125122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":59,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.2217\/fon-2019-0013"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0013","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}